Anti-Dihydropyrimidinase-related protein 1 [Nb394]

Description:

Recombinant monoclonal antibody to Dihydropyrimidinase-related protein 1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the alpaca peripheral blood lymphocytes Nb394.

Clone Name:

Nb394

Published Application(s):

WB, ELISA

Published Species Reactivity:

Human

UniProt Accession Number of Target Protein: Q14194

Alternative Name(s) of Target: CRMP1; DPYSL1; ULIP3; ULIP-3; DRP-1; CRMP-1; Collapsin response mediator protein 1; Unc-33-like phosphoprotein 3
Immunogen: The original antibody was isolated from a VHH library generated by immunization of an alpaca with whole glioblastoma multiforme (GBM) cells.

Specificity: This antibody binds human dihydropyrimidinase-related protein 1 (CRMP1). This protein is necessary for signaling by class 3 semaphorins and subsequent remodeling of the cytoskeleton. It is also involved in invasive growth and cell migration.

Application Notes: This antibody was used for identification of CRMP1 protein in cytosolic and membrane protein fractions of glioblastoma (GBM) tissues using western blotting. It was reported that CRMP1 expression was high in GBM compared to reference samples. It was reported that CRMP1 was a good marker to distinguish glioma tissues from reference tissues. ELISA was used for the screening of the nanobody library and identification of specific binders that showed specificity for GBM proteins (PMID: 28498803).

Antibody first published in: Jovčevska et al. Differentially expressed proteins in glioblastoma multiforme identified with a nanobody-based anti-proteome approach and confirmed by OncoFinder as possible tumor-class predictive biomarker candidates. Oncotarget. 2017 Jul 4;8(27):44141-44158. PMID:28498803
Note on publication: Describes the isolation of nanobodies against various antigens overexpressed in glioblastoma multiforme.